Article Text

other Versions

Download PDFPDF
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom
  1. Sudha Sundar1,2,
  2. Ranjit Manchanda3,
  3. Charlie Gourley4,
  4. Angela George5,
  5. Andrew Wallace6,
  6. Janos Balega1,
  7. Sarah Williams7,
  8. Yvonne Wallis8,
  9. Richard Edmondson9,
  10. Shibani Nicum10,
  11. Jonathan Frost11,
  12. Ayoma Attygalle12,
  13. Christina Fotopoulou13,
  14. Rebecca Bowen11,
  15. Dani Bell14,
  16. Ketankumar Gajjar15,
  17. Bruce Ramsay16,
  18. Nicholas J Wood17,
  19. Sadaf Ghaem-Maghami18,
  20. Tracie Miles19 and
  21. Raji Ganesan20
  1. 1Gynaecological Oncology, Pan-Birmingham Gynaecological Cancer Centre, Birmingham, UK
  2. 2Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
  3. 3Gynaecological Oncology, Barts Health NHS Trust, Barts Cancer Institute, London, UK
  4. 4University of Edinburgh Cancer Research UK Centre, Edinburgh, UK
  5. 5Royal Marsden Hospital NHS Trust, London, UK
  6. 6Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK
  7. 7University Hospital Birmingham Foundation NHS Trust, Birmingham, UK
  8. 8Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
  9. 9University of Manchester, Manchester, UK
  10. 10Oxford University Hospitals NHS Trust, Oxford, UK
  11. 11Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
  12. 12Pathology, Royal Marsden NHS Foundation Trust, London, UK
  13. 13Gynaecologic Oncology, Imperial Hospitals NHS trust, London, UK
  14. 14Macmillan Cancer Support, London, UK
  15. 15Nottingham University Hospitals NHS Trust, Nottingham, UK
  16. 16Peterborough City Hospital, Peterborough, Cambridgeshire, UK
  17. 17Obstetrics and Gynaecology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
  18. 18Imperial College London, London, UK
  19. 19Gynaecological Oncology, Royal United Hospitals, Bath, UK
  20. 20Birmingham Women’s and Children’s NHS Trust, Birmingham, UK
  1. Correspondence to Professor Sudha Sundar, Pan-Birmingham Gynaecological Cancer Centre, Birmingham B152TT, UK; sudha.sundar{at}nhs.net

Abstract

The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.

  • BRCA1 protein
  • BRCA2 protein
  • fallopian tube neoplasms
  • ovarian neoplasms

Statistics from Altmetric.com

Footnotes

  • Twitter @sundar_sudha, @ProfManchanda

  • Contributors The BGCS BAGP BRCA Consensus group drafted this guidance. SS and RG conceived the idea. All authors on the consensus group wrote the manuscript and reviewed the manuscript before submission. SS is guarantor.

  • Funding We thank Astra Zeneca for funding workshop expenses.

  • Disclaimer Funder had no role in consensus deliberations or writing the document.

  • Competing interests SS has received honoraria from Astra Zeneca outside the submitted work. CF has received honoraria from Ethicon, Tesaro, MSD/Astra Zeneca, Clovis, Roche, GSK. RM reports grants from Barts Charity, grants from The Eve Appeal, personal fees from Astra Zeneca, MSD, outside the submitted work. RB reports personal fees from GSK, personal fees from AstraZeneca, personal fees from Clovis, from Tesaro, outside the submitted work. RE reports personal fees from Astra Zeneca, personal fees from Clovis Pharma, personal fees from GSK, outside the submitted work.

  • Patient consent for publication Not required.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.